Memory & Focus+ IV Drip

About This IV

Memory & Focus+ is a mechanistically comprehensive neuro-cognitive IV formula designed around the complete biochemistry of neurotransmitter synthesis, neuronal energy metabolism, synaptic plasticity, and neuroprotection — the four independent pillars of cognitive performance. Unlike stimulant-based cognitive enhancers (caffeine, amphetamines) that temporarily increase catecholamine release at the expense of depleting neurotransmitter pools, Memory & Focus+ replenishes the rate-limiting precursors and enzymatic cofactors that determine the sustainable synthesis capacity of each major neurotransmitter system, producing cognitive enhancement that deepens over multiple sessions rather than attenuating. The formula's neurotransmitter synthesis strategy begins with Tryptophan (50mg) and Tyrosine (10mg) — the two aromatic amino acids that are the obligate precursors of the brain's primary monoamine neurotransmitters. Tryptophan is the sole dietary precursor for serotonin (5-hydroxytryptamine, 5-HT) — the neurotransmitter system governing mood stability, executive function, impulse control, working memory, and sleep-wake cycle regulation. The serotonin synthesis pathway is: Tryptophan → 5-hydroxytryptophan (5-HTP) via tryptophan hydroxylase (TPH2, the rate-limiting enzyme) → 5-HT via aromatic L-amino acid decarboxylase (AADC, B6-dependent). TPH2 has a Km for tryptophan of approximately 30–50 µM — significantly above the free plasma tryptophan concentrations typically present after dietary protein restriction, fasting, high exercise, or high-cortisol states (all conditions that reduce the ratio of free tryptophan to competing large neutral amino acids, LNAA, that compete for the same blood-brain barrier transporter). IV Tryptophan bypasses LNAA competition entirely — delivered directly to plasma at therapeutic concentrations with no gastric first-pass metabolism, 100% bioavailability, and no competition from co-administered dietary amino acids. The resulting spike in plasma free tryptophan maximally saturates the BBB neutral amino acid transporter (LAT1) and TPH2 in the raphe nuclei, restoring serotonergic tone in the prefrontal cortex, hippocampus, and amygdala — the three regions most critical for cognitive function, memory encoding, and emotional regulation. Tyrosine (10mg IV) is the precursor for both dopamine and norepinephrine — the catecholamine neurotransmitters governing reward anticipation, motivation, working memory maintenance, attentional focus, and the prefrontal-cortical executive function network. The catecholamine synthesis pathway is: Tyrosine → L-DOPA via tyrosine hydroxylase (TH, the rate-limiting enzyme, requires iron Fe²⁺ and Vitamin C as cofactor) → Dopamine via AADC (B6-dependent) → Norepinephrine via dopamine-β-hydroxylase (DBH, requires Vitamin C as obligate electron donor). Tyrosine hydroxylase activity is product-inhibited — high dopamine and norepinephrine inhibit TH via feedback — meaning tyrosine provision is rate-limiting specifically under conditions of high catecholamine demand (acute cognitive stress, sleep deprivation, high workload) rather than at baseline. At 10mg IV — a precise, targeted dose — Tyrosine replenishes the cytoplasmic tyrosine pool in dopaminergic neurons of the ventral tegmental area (VTA) and noradrenergic neurons of the locus coeruleus specifically when catecholamine synthesis demand is high, restoring TH substrate availability and catecholamine production without the receptor desensitisation that occurs with direct receptor agonists. The Pyridoxine B6 (100mg) in this formula is the obligate cofactor (as pyridoxal-5-phosphate, PLP) for AADC — the enzyme that converts both 5-HTP to serotonin AND L-DOPA to dopamine; B6 deficiency impairs both serotonin and dopamine synthesis simultaneously. At 100mg IV, Pyridoxine fully saturates AADC throughout the brain, ensuring that both the tryptophan-serotonin and tyrosine-dopamine pathways operate at maximum conversion efficiency. Hydroxocobalamin B12 (1.5mg) is required for the methylation cycle that maintains adequate SAM (S-adenosylmethionine) — the methyl donor for COMT (catechol-O-methyltransferase), which degrades catecholamines and regulates their synaptic half-life; B12 deficiency causes hyperhomocysteinemia which is neurotoxic and impairs methylation-dependent COMT activity, leading to dysregulated catecholamine signalling. Methylfolate B9 (1mg) drives the methionine cycle: folate → 5-methylTHF → methionine (via B12-dependent methionine synthase) → SAM. Trimethylglycine (600mg) provides the betaine-dependent alternative methylation pathway (betaine:homocysteine methyltransferase, BHMT) that regenerates methionine from homocysteine independently of B12 — providing methylation redundancy and ensuring SAM availability for neurotransmitter methylation reactions even in B12-insufficient states. Magnesium (1000mg) is the single most important mineral for cognitive function and is the highest-dosed component in this formula (besides Vitamin C) for this reason. Magnesium's neurological functions span four independent mechanisms: (1) NMDA receptor regulation — magnesium ions (Mg²⁺) are the physiological voltage-dependent blockers of the NMDA receptor (N-methyl-D-aspartate receptor) ion channel. At resting membrane potential, Mg²⁺ blocks the NMDA channel, preventing calcium entry. Only when the postsynaptic membrane is sufficiently depolarised by coincident AMPA receptor activation is Mg²⁺ expelled from the channel, allowing Ca²⁺ entry and triggering long-term potentiation (LTP) — the synaptic plasticity mechanism underlying learning and memory formation. Magnesium deficiency reduces this voltage-dependent block, allowing excessive NMDA receptor activation and Ca²⁺ entry that causes excitotoxic neuronal injury — the molecular basis of cognitive decline associated with chronic magnesium deficiency. (2) ATP-Mg²⁺ complexation — all ATP-utilising reactions in neurons (Na⁺/K⁺-ATPase for membrane potential restoration after action potentials, glutamate reuptake ATPases, vesicular monoamine transporters) require Mg²⁺-ATP as the actual substrate rather than free ATP. (3) GABA-A receptor positive allosteric modulation — magnesium at supra-physiological concentrations (achieved by 1000mg IV) acts as a GABA-A receptor positive modulator, reducing neuronal excitability and anxiety that impairs working memory and executive function. (4) Inhibition of voltage-gated calcium channels — Mg²⁺ competes with Ca²⁺ at voltage-gated calcium channels in presynaptic terminals, modulating neurotransmitter vesicle release and preventing the excessive presynaptic firing that contributes to glutamate excitotoxicity. N-Acetylcysteine (500mg) provides two distinct neuroprotective mechanisms. First, it replenishes brain glutathione (GSH) — the primary antioxidant defence of neurons against the high oxidative load generated by their intense energy metabolism (neurons consume 20% of the body's oxygen despite comprising 2% of body mass). Neuronal GSH depletion underlies the oxidative damage to synaptic mitochondria that impairs cognitive function and is a hallmark of neurodegenerative disease. Second, NAC modulates glutamate signalling: NAC is a precursor for cystine/glutamate antiporter (system Xc⁻) activity — this transporter imports cystine (for GSH synthesis) in exchange for glutamate export into the extracellular space, modulating perisynaptic glutamate concentrations and preventing the sustained glutamate receptor activation (non-NMDA excitotoxicity) associated with cognitive fatigue and anxiety. Vitamin C (5000mg) provides cofactors for both TH (tyrosine→L-DOPA) and DBH (dopamine→norepinephrine) as described above, while also serving as the brain's primary aqueous antioxidant — the CSF Vitamin C concentration is 4-fold higher than plasma under normal conditions, actively concentrated by the choroid plexus. At 5000mg IV, plasma Vitamin C achieves concentrations that maximally saturate the choroid plexus sodium-dependent Vitamin C transporter (SVCT2), restoring CSF Vitamin C to peak neuroprotective levels. Inositol (200mg) serves as the backbone of phosphatidylinositol (PI) species — specifically PI(4,5)P2 and PI(3,4,5)P3 — which are the second messengers for multiple neurotrophic receptor signalling cascades including BDNF/TrkB (brain-derived neurotrophic factor), NGF/TrkA (nerve growth factor), and the serotonin 5-HT2A and 5-HT2C receptors (which use IP3 as their second messenger). Inositol depletion is associated with depression, OCD, and panic disorder — all conditions of impaired serotonergic and neurotrophic signalling — and inositol supplementation at 200mg IV bypasses the rate-limiting enzyme of inositol synthesis (inositol-3-phosphate synthase) to directly restore PI precursor pools. Taurine (250mg) in the neurological context acts as a neuromodulator at GABA-A, glycine, and sigma-1 receptors — reducing anxious hyperarousal that fragments attention and working memory — and at the same time provides the τm5U mitochondrial tRNA modifications that maintain ETC efficiency in neurons and astrocytes (as detailed in the Energy Boost+ mechanism). Dexpanthenol B5 (500mg) is converted to Coenzyme A and then to acetyl-CoA — the immediate precursor for acetylcholine synthesis via choline acetyltransferase (ChAT). Acetylcholine is the primary neurotransmitter of the septohippocampal pathway governing episodic memory formation and hippocampal LTP. Dexpanthenol B5 at 500mg IV provides the highest B5 dose in the formula, reflecting the high priority of acetylcholine precursor provision for memory function specifically. Zinc (15mg) is an endogenous NMDA receptor modulator — Zn²⁺ ions are co-released with glutamate from zincergic neurons in the hippocampus and prefrontal cortex during high-frequency synaptic transmission, modulating the threshold for LTP induction. Zinc also inhibits HDAC (histone deacetylase) class I and II enzymes in neurons, promoting the chromatin accessibility required for synaptic plasticity-related gene expression (Arc, BDNF exon IV, c-Fos). Riboflavin B2 (5mg) provides FAD for MTHFR (methylenetetrahydrofolate reductase) — the enzyme that converts folate to 5-methylTHF (active folate, Methylfolate B9). MTHFR activity requires FAD; Riboflavin B2 deficiency functionally impairs the entire methylation cycle by reducing 5-methylTHF availability regardless of dietary folate intake. Selenium (0.05mg) activates selenoprotein P — the primary selenium transport protein in the brain, concentrated in astrocytes and required for GPx4 and TrxR expression in neurons — providing mitochondrial protection in high-energy-demand neuronal populations (hippocampal CA1, prefrontal cortex layer 5 pyramidal neurons) that are disproportionately vulnerable to selenoprotein P deficiency.